Literature DB >> 16440141

Feasibility and safety of thrombectomy with TVAC aspiration catheter system for patients with acute myocardial infarction.

Jin Yokoyama1, Motoi Kushibiki, Takayuki Fujiwara, Yujin Tamura, Naotaka Maeda, Takumi Higuma, Shingo Sasaki, Fuminobu Yoshimachi, Toshiro Matsunaga, Hiroyuki Hanada, Tomohiro Osanai, Ken Okumura.   

Abstract

Early reperfusion with angioplasty and stenting is established as a central, effective treatment for acute myocardial infarction (AMI). The role of thrombectomy prior to angioplasty remains to be elucidated. To evaluate its feasibility, safety, and efficacy, thrombectomy using a TVAC aspiration catheter system was attempted prior to angioplasty and stenting in 40 consecutive patients with AMI. Fifty consecutive patients with AMI in whom angioplasty and stenting were performed without prior thrombectomy served as controls. Neither distribution of Killip classification nor culprit lesion was different between the two groups. In patients treated with the TVAC system, the procedure was successful in 39/40 patients (98%) and there were no procedure-related complications. In the final coronary angiogram, TIMI-3 (Thrombolysis in Myocardial Infarction) flow was obtained in 37/40 (93%) in patients treated with the TVAC system and 43/50 (86%) in control patients. Electrocardiograms before and after coronary intervention were analyzed in patients with ST elevation AMI (35 patients treated with the TVAC system and 41 control patients). ST elevation recovery >50% of the initial value was observed after coronary intervention in 26/35 (74%) in patients treated with the TVAC system and 26/41 (63%) in control patients (P = 0.33). In the case of anterior AMI, ST elevation recovery >50% of the initial value was observed in 13/17 (76%) in patients treated with the TVAC system and 8/20 (40%) in control patients (P = 0.045). Thus, thrombectomy using a TVAC system is feasible, safe, and may have the potential to enhance ST-segment resolution in patients with anterior AMI.

Entities:  

Mesh:

Year:  2006        PMID: 16440141     DOI: 10.1007/s00380-005-0850-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   1.814


  23 in total

1.  Usefulness of the rescue PT catheter to remove fresh thrombus from coronary arteries and bypass grafts in acute myocardial infarction.

Authors:  V van Ommen; R Michels; E Heymen; J van Asseldonk; H Bonnier; J Vainer; H de Swart; J Koolen
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

Review 2.  Coronary plaque disruption.

Authors:  E Falk; P K Shah; V Fuster
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

3.  Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group.

Authors:  A W van 't Hof; A Liem; M J de Boer; F Zijlstra
Journal:  Lancet       Date:  1997-08-30       Impact factor: 79.321

4.  Primary stent implantation without coumadin in acute myocardial infarction.

Authors:  S Saito; F G Hosokawa; K Kim; S Tanaka; S Miyake
Journal:  J Am Coll Cardiol       Date:  1996-07       Impact factor: 24.094

5.  Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.

Authors:  M M Khan; S G Ellis; F V Aguirre; H F Weisman; N M Wildermann; R M Califf; E J Topol; N S Kleiman
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

6.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.

Authors:  F Zijlstra; M J de Boer; J C Hoorntje; S Reiffers; J H Reiber; H Suryapranata
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

7.  Diagnosing and managing unstable angina. Agency for Health Care Policy and Research.

Authors:  E Braunwald; R H Jones; D B Mark; J Brown; L Brown; M D Cheitlin; C A Concannon; M Cowan; C Edwards; V Fuster
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

8.  Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis.

Authors:  A G Violaris; R Melkert; J P Herrman; P W Serruys
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

9.  Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome.

Authors:  Jun-ichi Kotani; Shinsuke Nanto; Gary S Mintz; Masafumi Kitakaze; Tomoki Ohara; Takakazu Morozumi; Seiki Nagata; Masatsugu Hori
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

10.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  3 in total

1.  Manual versus nonmanual thrombectomy in primary and rescue percutaneous coronary angioplasty.

Authors:  Giandomenico Tarsia; Mario De Michele; Domenico Polosa; Giuseppe Biondi-Zoccai; Fabio Costantino; Giuseppe Del Prete; Rocco Aldo Osanna; Pasquale Innelli; Francesco Sisto; Imad Sheiban; Pasquale Lisanti
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

2.  Use of Thrombectomy Devices in Primary Percutaneous Interventions for ST-elevation Myocardial Infarction - An Update.

Authors:  Krishnaraj S Rathod; Stephen M Hamshere; Tawfiq R Choudhury; Daniel A Jones; Anthony Mathur
Journal:  Interv Cardiol       Date:  2014-04

3.  Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for acute ST elevation MI: a meta-analysis of randomized controlled trials.

Authors:  Umesh U Tamhane; Stanley Chetcuti; Irfan Hameed; P Michael Grossman; Mauro Moscucci; Hitinder S Gurm
Journal:  BMC Cardiovasc Disord       Date:  2010-02-26       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.